Nuformix Plc‘s (LON:NFX) latest NXP002 preclinical results have given the company important new evidence as it looks to advance its inhaled treatment for idiopathic pulmonary fibrosis. Executive Director Dr Dan Gooding explains how the study demonstrated therapeutically relevant drug concentrations in the lung alongside fibrosis-related pathway engagement, why the findings support the potential therapeutic window for NXP002 and how the data can now help shape the programme’s next toxicology studies. He also discusses ongoing target-identification work, the company’s funding position and why upcoming meetings with prospective pharma partners at the European Respiratory Society Congress in Barcelona could be an important next step.
Key Moments
00:32 — Why NXP002 is targeting a major IPF treatment gap
01:40 — The rationale for inhaled delivery
03:25 — Therapeutically relevant lung exposure demonstrated
05:17 — Data opens the way to the next development step
06:05 — What prospective pharma partners want to see
07:20 — Target-identification work gathers pace
09:21 — Nuformix outlines its funding position
09:43 — Toxicology planning and target discovery move forward
11:08 — Barcelona puts partnering discussions centre stage
11:31 — Existing and new pharma conversations continue
Nuformix is a pharmaceutical development company focused on developing new formulations of existing drugs for areas of unmet medical need. Its lead programme, NXP002, is being developed as an inhaled treatment for fibrotic lung diseases including idiopathic pulmonary fibrosis, with the company working towards further preclinical development and potential partnering opportunities.
